Mergers and Acquisitions

The acquisition was completed through the merger of a wholly owned subsidiary of Sanofi with and into Provention Bio.

GSK has reached an agreement to acquire late-stage biopharmaceutical company BELLUS Health.

Ginkgo Bioworks has acquired StrideBio's AAV capsid discovery and engineering platform and has formed a partnership with WARF for development of next-gen cell therapies.

The acquisition of Cell Systems will bolster AnaBios’ portfolio of human tissue and cells for use in drug discovery.

Ingredion has completed two strategic investments in India with Amishi Drugs & Chemicals and Mannitab Pharma Specialties.

Sumitovant Bipharma has completed its acquisition of Myovant Sciences for approximately $1.7 billion.

Pharmapack Europe experts expect smaller and medium European packaging companies to grow or be acquired.

The partnership led to Asimov licensing its clonal GMP HEK293 suspension cell line to CBM for pre-clinical and clinical production of viral vectors for its clients.

The merged company will operate under the name Ayala Pharmaceuticals and will target the development and commercialization of Ayala’s lead program, AL102, for the treatment of desmoid tumors.

Snapdragon Chemistry concentrates in API batch and continuous flow process development, utilizing state-of-the-art automation technology and proprietary equipment to solve complex process and analytical development challenges.

The Vault Quality Suite will help Adare simplify its quality operations across its sites in the United States, France, and Italy.

It is intended to identify the most prevalent and immunogenic targets in solid tumors by uniquely combining high-diversity target libraries with active machine learning.

Astrea Bioseparations has acquired Delta Precision, a manufacturer of chromatography columns for biomanufacturing.

Bio/pharma has evolved and adapted to a variety of challenges in 2022, but what might be on the cards for the industry in 2023?

CMOs are hoping to grow outsourcing to significantly higher levels in many different areas, with a focus on analytical testing, toxicity testing, and fill/finish operations.

In addition, personnel, equipment, and facilities from the acquired companies will expand Reaction Biology’s presence in Germany while enabling its global customers to leverage Bioassay’s expansive portfolio of regulated clinical and commercial services.

Cytiva’s acquisition of CEVEC Pharmaceuticals strengthens the company’s cell line development and biomanufacturing capabilities.

H.I.G. Capital’s portfolio company Aspire Pharma has acquired Morningside Healthcare and Morningside Pharmaceuticals.

Pfizer has completed its acquisition of Biohaven Pharmaceuticals for approximately $11.6 billion.

Actylis combines Aceto and its 10 acquired specialists into a singular global brand.

Avance Clinical’s acquisition of C3 Research Associates expands its CRO services to North America.

ChargePoint Technology has acquired single-use container company PuroVaso.

Catalent will acquire Metrics Contract Services for $475 million to expand high-potent capabilities and oral development and manufacturing capacity.

Amgen’s acquisition of Chemocentryx includes the autoimmune disease drug Tavneos (avacopan).

CRYOPDP is expanding its footprint to Spain with its acquisition of Polar Expres.

GSK has completed its demerger of Haleon and has signed an agreement to help support future pandemic preparedness in Europe.

As a result of the disruptions caused by the COVID-19 pandemic, global arbitration has adapted to a ‘new normal’.

Boehringer Ingelheim has signed an option to acquire Trutino Biosciences.

Advanz Pharma has signed an agreement with Intercept Pharmaceuticals to acquire most of the its subsidiaries and non-US operations.

GSK reaches agreement to acquire late-stage biopharmaceutical company Sierra Oncology for $1.9 billion.